1260 (1260) Fair Value & Analysis

Industrials · Market cap HK$507M

1 1260 1260 · HK

PriceHK$0.4400

Fair ValueHK$1.03

Upside+134.1%

Quality63/100

Evidence: High Range HK$0.8600 – HK$1.03

Fair value as of: Jul 2, 2026

From 22 valuation models · updated today

Share price −15.4% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$0.3750 – HK$0.5700 · fair‑value band HK$0.8600 – HK$1.03 · the HK$0.4400 price screens below the HK$1.03 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

1260 (1260) currently trades at HK$0.4400, while our model-based Fair Value estimate is HK$1.03 — implying the stock looks roughly 134.1% undervalued today. We read business quality at 63/100 (solid quality), in the Industrials sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

Over the trailing twelve months, 1260 generated revenue of HK$235M at a net margin of 29.6%. Revenue grew 49.1% year over year. It earns a return on equity of 4.5%. The balance sheet holds a net cash position of HK$28.7M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$235M

Revenue growth (YoY) +49.1%

Net margin 29.6%

Return on equity 4.5%

Free cash flow HK$54.2M FY2025

P/E ratio 7.3

More key figures

Operating margin 22.5%

EPS (TTM) HK$0.0100

EPS growth (YoY) +99.5%

Net cash HK$28.7M FY2026

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

1260 reported revenue of HK$260M in FY2026 versus HK$304M in FY2022, a compound −3.8%/yr. Reported net income was HK$85.2M in FY2026.

Revenue −3.8%/yr

FY22 HK$304M

FY23 HK$276M

FY24 HK$239M

FY25 HK$191M

FY26 HK$260M

Net income

FY22 −HK$129M

FY23 HK$27.2M

FY24 −HK$66.5M

FY25 HK$41.2M

FY26 HK$85.2M

Is 1260 fairly valued? → Check now

Similar stocks

6 more Specialty Business Services stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
Cintas Corporation CTAS	$169.45	$82.75	-51%
RELX PLC R1EL34	R$45.28	R$23.22	-49%
Thomson Reuters Corporation TRI	C$108.50	C$70.40	-35%
Copart, Inc CPRT	$30.77	$28.89	-6%
Global Payments Inc GPN	$65.09	$70.80	+9%
UL Solutions Inc ULS	$96.81	$77.22	-20%

Explore undervalued stocks

More undervalued Industrials stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 1260 (1260) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$1.03 versus a price of HK$0.4400 — about +134% (undervalued). Model-based estimate, not financial advice.

What is the fair value of 1260?

Our model-based fair value for 1260 is HK$1.03 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$0.4400.

What is the quality score of 1260?

1260 has a Quality Score of 63/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 1260 (1260)?

1260 reported trailing-twelve-month revenue of about HK$235M (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 1260?

The net profit margin of 1260 is about 29.6%, meaning it keeps roughly 29.6% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.